ETF Components for AADR - WCM BNY Mellon Focused Growth ADR ETF


Below is a list of stocks held by this ETF. We only list holdings in the same market. If this is a global ETF, there may be additional components other than those listed here.

Holdings

Symbol Grade Price % Change Allocation
NVO C -1.43 6.40
YPF A -2.05 4.70
MUFG C 1.03 3.36
ABBV C 0.25 3.28
BBVA A 1.20 3.20
BMA A 0.46 3.18
CX B -1.22 3.14
GGAL A 1.26 3.09
ERJ A -0.74 3.09
ASX B -2.27 2.86
RELX C -0.05 2.79
HMY A 0.44 2.79
FMX C 0.11 2.67
PAM D -0.31 2.66
SAP C -0.72 2.66
NMR B 0.17 2.53
KOF C 1.36 2.52
TNP B -3.01 2.50
ING A 1.13 2.36
PBR C -0.70 2.35
MELI D -1.98 2.33
NXPI D -3.34 2.26
SMFG B 0.36 2.25
LOGI D -1.16 2.24
VIPS D -1.17 1.95
AVDL A -3.39 1.92
E A -1.20 1.81
VIV D -0.54 1.69
ELP F 0.14 0.82

Recent News for WCM BNY Mellon Focused Growth ADR ETF & its Holdings

Date Stock Title
Apr 18 VIPS Why Vipshop Holdings Limited (VIPS) Dipped More Than Broader Market Today
Apr 18 ABBV Soon To Be Acquired Cerevel Therapeutics Reveals High Level Data From Late-Stage Parkinson's Disease Study
Apr 18 PBR Petrobras' (PBR) Buzios Field Achieves Production Milestone
Apr 18 ABBV AbbVie Q1 Earnings Preview: No Repeat Of Last Year's Q1 Disappointment
Apr 18 NVO India's Biocon developing its own version of Wegovy, clinical trial likely next year
Apr 18 ABBV Heard on the Street: AbbVie’s Bet on a Neuroscience Drug Maker Just Got Better
Apr 18 MELI MercadoLibre: Best Quarter In Recent Memory
Apr 18 NVO How The Weight-Loss Bonanza Prompted A ResMed Sell-Off — But Could Soon Drive Shares Higher
Apr 18 RELX RELX PLC (LON:REL) is largely controlled by institutional shareholders who own 71% of the company
Apr 18 ABBV AbbVie succeeds in late-stage trial for Rinvoq in inflammatory condition
Apr 18 NVO Eli Lilly's (LLY) Tirzepatide Meets Goals in Sleep Apnea Studies
Apr 18 ABBV Phase 3 SELECT-GCA Study of Upadacitinib (RINVOQ®) Showed Positive Results in Patients With Giant Cell Arteritis
Apr 18 ABBV AbbVie buyout Cerevel posts late-stage win for Parkinson’s disease drug
Apr 18 ABBV Cerevel, in ‘major surprise,’ finds success in late-stage Parkinson’s study
Apr 18 PBR Brazil's plans to drill for oil in the Amazon hit stiff Indigenous resistance
Apr 18 SAP Investors in SAP (ETR:SAP) have seen favorable returns of 61% over the past five years
Apr 18 NVO Metsera, a well-funded obesity drug startup, sees chance to challenge Lilly, Novo
Apr 17 ABBV AbbVie (ABBV) Increases Despite Market Slip: Here's What You Need to Know
Apr 17 PBR UPDATE 1-Petrobras board not to discuss extra dividends at Friday meeting, sources say
Apr 17 PBR Petrobras Chair Returns to Board Divided by Rivalries
The investment seeks long-term capital appreciation above international benchmarks such as the BNY Mellon Classic ADR Index, the fund's primary benchmark, and the MSCI EAFE Index, the fund's secondary benchmark. The sub-advisor seeks to achieve the fund's investment objective by selecting primarily a portfolio of U.S.-traded securities of non-U.S. organizations, most often American Depositary Receipts ("ADRs"), included in the BNY Mellon Classic ADR Index. The fund's investment focus follows the Sub-Advisor's core philosophy of investing in industry-leading non-U.S. organizations led by visionary management teams with sound business strategies.
Exchange Traded Fund ETF MSCI EAFE American Depositary Receipt
Back to the Main AADR Page...